Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

Blood

Volumn 100, Issue 4, 2002, Pages 1201-1207

  Joachim Deeg, H ^a,b   Storer, Barry ^a,b   Slattery, John T ^a,b   Anasetti, Claudio ^a,b   Doney, Kristine C ^a,b   Hansen, John A ^a,b   Kiem, Hans Peter ^a,b   Martin, Paul J ^a,b   Petersdorf, Effie ^a,b   Radich, Jerald P ^a,b   Sanders, Jean E ^a,b   Shulman, Howard M ^a,b   Warren, Edus H ^a,b   Witherspoon, Robert P ^a,b   Bryant, Eileen M ^a,b   Chauncey, Thomas R ^a,b   Getzendaner, Lisa ^a,b   Storb, Rainer ^a,b   Appelbaum, Frederick R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DRUG BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; ORGAN DONOR; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SCORING SYSTEM; STEADY STATE; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

EID: 0037103191     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0527     Document Type: Article

References (43)

1. Proposals for the classification of the myelodysplastic syndromes
2. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997
3. International scoring system for evaluating prognosis in myelodysplastic syndromes
4. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
5. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia
6. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes
7. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation
8. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
9. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes
10. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable non-relapse mortality
11. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors
12. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
13. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
14. Relapse after allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS) subtype refractory anemia (RA) is increased by shielding lungs and liver during irradiation
15. Graftrejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
16. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation
17. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors
18. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation
19. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
20. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation
21. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation
22. Graft-versus-host-disease
23. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): Safety analysis
24. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
25. A humanized non-FCR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
26. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay
27. The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry
28. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers
29. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry
30. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation
31. Nonparametric estimation from incomplete observations
32. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators
33. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: Comparison with unrelated donor transplantation and autologous stem cell transplantation
34. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
35. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors
36. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
37. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French Society of bone marrow transplantation
38. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy
39. Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program
40. Blood or marrow?
41. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
42. A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow transplantation in 350 patients (pts) with leukemia
43. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial